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Introduction
Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disorder, caused by deficiency of the enzyme arylsulfatase A (ARSA, E.C. 3.1.6.1) with a frequency of approximately 1 per 40,000 worldwide. 1 ARSA catalyzes initiative step of the metabolic pathway, sphingolipid 3′-o-sulfogalactosylceramide, known as sulfatide. Sulfatide is especially abundant in the myelin sheath of the nervous system. 2 Mutations in the ARSA gene ( Figure 1 ) (GenBank accession number NP_000478) could lead to a deficiency in ARSA activity, leading to accumulation of sulfatide, especially in the nervous system. 3, 4 This phenomenon causes a progressive demyelination that leads to different neurological symptoms including ataxia, an initially flaccid and later spastic paresis, optic atrophy, and dementia. 5 To date, there is no effective treatment for MLD. However, bone marrow transplantation and stem cell therapy can be beneficial for patients with juvenile-and adult-onset forms in the early stages of the disease. In addition, gene and enzyme replacement therapies for the treatment of MLD have shown promising outcomes in mice models. [6] [7] [8] [9] [10] [11] ARSA deficiency is divided into 3 clinical subtypes: late-infantile (50%-60%), juvenile (20%-30%), and adult (15%-20%). The disorder course may range from 3 to 10 years or more in the late-infantile type and up to 20 years in the juvenile and adult types. In addition, there is elevated white matter involvement, including U-fibers and cerebellar white matter, as well as cerebral atrophy with progression of the MLD disease. [13] [14] [15] [16] In this study, the ARSA gene was examined in individuals who met the proposed clinical criteria for MLD in order to identify the pathogenic impact of the associated mutations in MLD. enzymatic aRsa activity assay ARSA activity was determined in leukocytes using p-nitrocatechol sulfate as described previously by Molzer et al. 17 neuroimaging (MRi) analysis T2-weighted spin-echo sequences of the brain were carried out using a Siemens Magnetom Avanto 1.5 Tesla MRI (Munich, Germany). Images were evaluated in a blind fashion by a neuroradiologist.
Materials and methods
Patient collection and ethical statement
Dna extraction and polymerase chain reaction (PCR)
The genomic DNA was extracted from the blood samples of MLD patients by the QIAamp DNA Micro Kit (Qiagen #56304). PCR primers 18 for amplification of exons 1-8 of the ARSA gene are as indicated in Table 2 . Briefly, PCR was carried out in final volumes of 25 µL, containing 100-200 ng of total genomic DNA, 10 pmol of forward and reverse primers, 2.5 mM of MgCl 2 , 200 mM of each 
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Four novel ARSA gene mutations deoxyribonucleoside triphosphates (dNTP), and 1 U of super Taq DNA polymerase (Roche Diagnostics, Mannheim, Germany). The PCR mixture was cycled for 35 times at 95°C for 1 minute; annealing temperature was based on temperature (TM) (°C) of forward and reverse primers ( Table 2 ). The PCR products were examined on 2% agarose gel electrophoresis ( Figure 2 ) in 0.5× Tris-borate-EDTA (TBE) buffer at 110 V for 50 minutes, and then stained with 0.002 mg/mL EtBr solution and visualized using ultraviolet light.
Dna sequencing and bioinformatics analysis
The PCR products were sequenced by forward or reverse primers on an ABI 3700 sequencer (Kosar Company, Tehran, Iran) and the results were compared using Finch TV program and were then analyzed on the NCBI website (http://blast. ncbi.nlm.nih.gov/Blast.cgi). Moreover, the target sequence of patient was compared with normal reference sequence and ARSA gene mutations in exons and the splicing sites of the introns were identified. The functional and structural impacts of identified novel mutations in ARSA gene were assessed using in silico prediction algorithms including SIFT, 
statistical analysis
The chi-square test was used with Statistical Package for the Social Sciences (version 13) to examine the association between patient and healthy control samples, whereas P-value ,0.05 was considered statistically significant. exon 4, A.G 96 relative to termination codon homozygous mutation, W195C homozygous mutation in exon 3, and c.978+1G.A homozygous mutation in intron 5 were detected as presented in Table 3 . The 4 new mutations c.585G.T, c.661T.A, c.849C.G, and c.911A.G were significantly (P,0.05) identified in 4 patients (Table 4 and Figure 4A-D) . The possible structural and functional effects of identified new mutations in ARSA were examined using the bioinformatics SIFT, PolyPhen, and I-Mutant 2.0 software. Here, SIFT outcomes showed that W195C, F221I, D283E, and K340R mutations were determined as deleterious with scores of -0.734, -5.852, -3.908, and -2.931, respectively. I-Mutant analysis, based on the free energy change value (sign of DDG), demonstrated that p.W195C, p.F221I, p.D283E, and p.K340R mutations decreased protein stability. According to the PolyPhen score, the c.585G.T, c.661T.A, c.849C.G, and c.911A.G mutations were determined as probably damaging the protein structure and function with scores of 0.994, 1.000, 1.000 and 1.000, respectively (Table 4) . Notes: novel pathogenic mutations were examined using 3 computational methods to assess the structural and functional impacts of novel amino acid changes: PolyPhen 2 (benign or damaging), siFT (tolerated or deleterious), and i-Mutant 2.0 (increase or decrease stability). PolyPhen prediction score: benign (#0.5) and probably damaging (0.5,). siFT prediction score: tolerated ($0.05) and deleterious (#0.05). i-Mutant 2.0 prediction: Free energy change value (DDg): decreasing or increasing protein stability. Abbreviations: siFT, sorting intolerant from tolerant; DDg, the predicted free energy change value. .A mutation in P11 that were reported by Gort et al, 21 Gieselmann et al, 22 Hasegawa et al, 23 Harvey et al, 24 Kreysing et al, 25 Gieselmann et al, 26 and Eng et al, 27 respectively. Hence, additional research is required to affirm the biological role of these pathogenic mutations and confirm the in silico bioinformatics findings that have shown possible effects on protein structure and/or function in the absence of the ARSA enzyme.
Results
At
The ARSA gene has 8 exons, which are located on chromosome 22 (22q13.33). 25 At present, more than 150 mutations were identified in the ARSA gene according to the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ ac/gene.php?gene=ARSA) ( Figure 5 ).
MLD is a heterogeneous disease with 3 frequent defective alleles including a missense mutation that leads to a Ilel79Ser substitution, a splice donor-site mutation at the exon 2/intron 2 border, and a missense mutation that causes a Pro246Leu substitution, which account for 12%, 25% (among European patients), and 25% of all defective alleles, respectively. 28, 29 Other mutant alleles were reported in only a few or single patients.
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Conclusion
The result of this research has broadened the genotypic spectrum of Iranian patients with MLD, paving way to a more
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